4,174 Shares in Cencora, Inc. $COR Bought by AlphaGrep UK Ltd

Key Points

• AlphaGrep UK Ltd purchased 4,174 Cencora shares worth approximately $1.18 million, making the stock about 0.4% of its portfolio. Institutional investors collectively own 97.52% of Cencora.
• Cencora exceeded quarterly earnings expectations, reporting $4.48 in EPS and $84.75 billion in revenue, with revenue up 5.1% year over year. The company also maintains a $2.40 annualized dividend and authorized a $2 billion share-repurchase program.
• Analysts remain broadly positive, with 13 Buy ratings and three Holds, producing a consensus “Moderate Buy” rating and an average price target of $370.85.

AlphaGrep UK Ltd purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,174 shares of the company's stock, valued at approximately $1,181,000. Cencora comprises approximately 0.4% of AlphaGrep UK Ltd's holdings, making the stock its 25th largest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Kemnay Advisory Services Inc. acquired a new position in Cencora in the fourth quarter valued at $25,000. Elyxium Wealth LLC bought a new stake in Cencora in the fourth quarter valued at $27,000. Elevation Wealth Partners LLC grew its stake in Cencora by 506.2% in the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company's stock valued at $27,000 after acquiring an additional 81 shares during the period. Bell Investment Advisors Inc bought a new stake in shares of Cencora during the second quarter valued at approximately $28,000. Finally, Caitlin John LLC bought a new stake in shares of Cencora during the second quarter valued at approximately $28,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Down 2.0%

Shares of NYSE COR opened at $330.52 on Friday. The firm has a market capitalization of $63.07 billion, a PE ratio of 24.56, a price-to-earnings-growth ratio of 1.91 and a beta of 0.57. The firm has a fifty day simple moving average of $312.33 and a two-hundred day simple moving average of $309.88. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping analysts' consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%.The firm had revenue of $84.75 billion for the quarter, compared to analysts' expectations of $84.31 billion. During the same period in the prior year, the firm posted $4.00 earnings per share. The company's quarterly revenue was up 5.1% on a year-over-year basis. Equities analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Friday, August 14th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, August 14th. Cencora's payout ratio is currently 17.83%.

Cencora announced that its Board of Directors has initiated a stock buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts recently commented on COR shares. UBS Group increased their price target on Cencora from $412.00 to $430.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Robert W. Baird set a $370.00 price target on shares of Cencora in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $382.00 to $390.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Evercore restated an "outperform" rating and set a $350.00 price target on shares of Cencora in a report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Cencora from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $370.85.

Insiders Place Their Bets

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares of the company's stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company's stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.38% of the stock is owned by corporate insiders.

About Cencora

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source